Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $33M seed (Mar 2026). Owkin Dx spinout. Multimodal oncology AI analyzing pathology images + clinical data for treatment decisions. Positioned against Tempus and Foundation Medicine.
Waiv is a digital pathology AI company spun out of Owkin's diagnostic unit in March 2026 with a $33 million seed round, inheriting Owkin's proven multimodal oncology AI stack that has been validated in multiple peer-reviewed publications and clinical collaborations with major academic medical centers. The platform analyzes H&E-stained pathology slide images combined with genomic, clinical, and outcomes data to extract prognostic and predictive biomarkers that help oncologists select optimal treatments for individual cancer patients.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.